PROCEPT BioRobotics Corporation Announces Appointment of Dr. Michael Mack as Member of the Board, Effective October 2, 2026
PROCEPT BioRobotics Corporation has announced the appointment of Dr. Michael Mack to its Board of Directors, effective October 2, 2026. Dr. Mack, a distinguished cardiac surgeon with extensive leadership experience and over 1,100 peer-reviewed publications, will serve as a Class II independent director until the company's 2029 annual meeting. This strategic addition aims to strengthen the board with Dr. Mack's medical expertise and leadership in healthcare.
Lawsuit filed against PROCEPT BioRobotics over alleged misleading sales practices and financial risks.
A lawsuit has been filed against PROCEPT BioRobotics Corporation, alleging that the company misled investors by failing to disclose a discount program that artificially inflated U.S. handpiece sales, leading to overstocking and undisclosed financial risks. The complaint, filed on July 24, 2026, claims that PROCEPT's public statements were false or misleading, and investors who purchased shares are advised to contact the Shareholders Foundation regarding the securities class action lawsuit.
Bank of America Corp DE Purchases 516,198 Shares of PROCEPT BioRobotics Corporation $PRCT
Bank of America Corp DE recently acquired 516,198 shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, valued at approximately $11.7 million, representing 0.9% of the company. Institutional investors and hedge funds own a significant 89.46% of PRCT, while insiders, including CEO Larry Wood who purchased 23,900 shares, hold about 4%. Despite a consensus "Hold" rating from analysts and a price target of $25.09, PRCT opened at $17.20 after reporting a 19.3% increase in quarterly revenue but a larger-than-expected loss per share.
PROCEPT BioRobotics Corporation (PRCT) options chain – Yahoo Finance
This article provides an options chain for PROCEPT BioRobotics Corporation (PRCT), detailing call and put options with various strike prices, last prices, changes, volumes, and open interest. The data includes options expiring on April 16, 2027. The stock PRCT was trading at 17.25 with a slight gain at market close.
PROCEPT BioRobotics Extends CIBC Term Loan Maturity to Oct 2028 Under Third Amendment
PROCEPT BioRobotics has extended the maturity date of its term loan with Canadian Imperial Bank of Commerce from October 1, 2027, to October 1, 2028, through a Third Amendment to its Loan and Security Agreement. This change aims to enhance the company's financial flexibility by extending its debt timeline, with other covenants remaining unchanged. The agreement was signed and became effective on September 23, 2026.
Form 8K Procept Biorobotics Corp For: 24 September By Investing.com
This article announces the filing of a Form 8K by Procept Biorobotics Corp for September 24th, as reported by Investing.com. It is a brief, one-sentence news item indicating a regulatory filing by the company. The article provides no further details about the content of the Form 8K.
PRCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of PROCEPT BioRobotics Corporation to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ:PRCT) and some of its officers. The lawsuit alleges that PROCEPT BioRobotics made false and misleading statements about its business practices, including using significant discounts to inflate revenue and overstating handpiece utilization. Investors who purchased PROCEPT BioRobotics securities between February 28, 2024, and February 25, 2026, are encouraged to contact the firm to join the case, with a lead plaintiff deadline of September 22, 2026.
Procept BioRobotics extends loan maturity date with CIBC by one year
Procept BioRobotics has extended its loan maturity date with Canadian Imperial Bank of Commerce (CIBC) by one year, moving it to October 1, 2028. This amendment maintains the company's strong balance sheet with $77.5 million in total debt and a current ratio of 6.55. The company recently reported a 19% increase in Q2 revenue but adjusted its full-year outlook for U.S. procedures downward due to softer-than-expected growth.
PROCEPT BioRobotics stock falls 4.04 percent on Nasdaq
PROCEPT BioRobotics stock (PRCT) fell 4.04% on Nasdaq, trading at USD 17.36. This comes after the company reported a 19.3% year-over-year revenue increase in Q2 2026, but also an adjusted loss that missed consensus estimates. The stock's performance is further complicated by a legal class action and a divided analyst outlook.
Important Notice to Long-Term Shareholders of Doximity,
Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Doximity, Inc. (NYSE: DOCS), GoDaddy Inc. (NYSE: GDDY), Planet Fitness, Inc. (NYSE: PLNT), and PROCEPT BioRobotics Corporation (NASDAQ: PRCT). The investigations concern alleged breaches of fiduciary duties by company officers and directors, following federal securities class action lawsuits. Shareholders who held shares before specific dates are encouraged to contact the law office to explore options for corporate reforms and recovery of funds.
Engineers Gate Manager LP Sells 101,942 Shares of PROCEPT BioRobotics Corporation $PRCT
Engineers Gate Manager LP significantly reduced its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by selling 101,942 shares, retaining 20,300 shares valued at $458,000. Despite this sale, institutional ownership remains high at 89.46%, with other major firms like BlackRock and Bank of America establishing new positions. PRCT shares opened at $18.09, and the company reported 19.3% revenue growth but a larger-than-expected loss, while analysts maintain a consensus "Hold" rating with an average price target of $25.09.
PROCEPT BioRobotics Corporation (PRCT) Stock Price, News, Quote & History
This article provides a detailed financial overview of PROCEPT BioRobotics Corporation (PRCT), including its current stock price, historical performance, key financial metrics, and analyst insights. It highlights the company's focus on developing robotic systems for urologic surgery, particularly for benign prostatic hyperplasia. The report also includes performance comparisons against the S&P 500 and lists recent earnings trends.
Kaplan Fox Continues to Alert Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Class Action Deadline on September 22, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a class action lawsuit filed on behalf of purchasers of PROCEPT common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT's discount program artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward demand. Investors who suffered losses may join the case, with a lead plaintiff deadline of September 22, 2026.
Class Action Lawsuit Filed: PROCEPT BioRobotics Corporation (PRCT) - Join by September 22, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who suffered losses from February 28, 2024, to February 25, 2026. The lawsuit alleges that Procept misled investors by using an undisclosed discount program that artificially inflated sales and revenues, leading to an overstock of handpiece units and an inability to meet future guidance. Shareholders are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery.
Kaplan Fox Continues to Alert Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Class Action Deadline on September 22, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a class action lawsuit deadline of September 22, 2026. The lawsuit alleges that PROCEPT's undisclosed discount program artificially inflated its reported U.S. handpiece unit sales and revenues. Investors who purchased PROCEPT common stock between February 28, 2024, and February 25, 2026, and have suffered losses are encouraged to contact Kaplan Fox to learn more about serving as a lead plaintiff.
Robbins LLP Reminds PROCEPT BioRobotics Corporation Stockholders of the September 22, 2026 Lead Plaintiff Deadline in the PRCT Securities Class Action Lawsuit
Robbins LLP is reminding investors of the upcoming September 22, 2026 lead plaintiff deadline in a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT). The lawsuit alleges that PROCEPT made materially false or misleading statements regarding its business and financial condition, specifically related to an undisclosed discount program that artificially inflated sales and led to significant overstocking of handpiece units. The company's stock fell more than 18% after these issues were revealed.
Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors
The Portnoy Law Firm has announced a class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased securities between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT engaged in an undisclosed discount program to inflate sales, leading to overstated handpiece unit sales and revenues. This program resulted in significant overstocking, ultimately causing substantial drops in the company's stock price after the underlying issues were revealed in earnings reports.
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT misled investors by claiming consistent handpiece unit sales and procedures, when in fact a discount program caused handpiece orders to artificially exceed procedures, inflating revenues. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of September 22, 2026.
Deadline Alert: PROCEPT BioRobotics Corporation (PRCT)
Glancy Prongay Wolke & Rotter LLP is urging investors who lost money on PROCEPT BioRobotics Corporation (PRCT) securities to contact them regarding a securities fraud lawsuit. The deadline to file a lead plaintiff motion is September 22, 2026. The lawsuit alleges that PROCEPT made misleading statements about its business operations and financial condition, specifically concerning an undisclosed discount program that artificially inflated handpiece sales.
TUESDAY PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for purchasers of common stock between February 28, 2024 and February 25, 2026. Investors with substantial losses have until Tuesday, September 22, 2026, to seek appointment as lead plaintiff. The lawsuit alleges that Procept made materially false and/or misleading statements regarding its business, operations, and financial condition, specifically concerning an undisclosed discount program that artificially inflated sales and revenues, leading to a significant overstock of handpieces.
Bragar Eagel & Squire, P.C Urges PROCEPT BioRobotics Corporation Investors to Contact the Firm Seeking Lead Plaintiff Role Before September 22nd
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that Procept misled investors by failing to disclose an extensive discount program that artificially inflated sales and revenues, leading to an oversupply of handpiece units. Investors have until September 22, 2026, to apply to be appointed as lead plaintiff.
INVESTOR DEADLINE: PROCEPT BioRobotics Corporation (PRCT) Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who purchased shares between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT withheld crucial information regarding its handpiece sales practices, including an extensive discount program that artificially inflated sales by incentivizing bulk orders. Investors are encouraged to join the class action lawsuit before the September 22, 2026, deadline.
PRCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased securities between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements by failing to disclose that it used significant discounts to inflate revenue, thereby misrepresenting its financial performance and product utilization. Investors are encouraged to contact the firm by September 22, 2026, to potentially serve as lead plaintiff.
PROCEPT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action – PRCT
The Rosen Law Firm is reminding investors who purchased PROCEPT BioRobotics Corporation (PRCT) common stock between February 28, 2024, and February 25, 2026, of the September 22, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its discount program, which artificially inflated sales and revenues, leading to a surplus of inventory and undisclosed risks. Investors are encouraged to contact the firm to join the class action.
PROCEPT BIOROBOTICS CORPORATION INVESTORS WITH LOSSES HAVE
Bernstein Liebhard LLP reminds investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with losses that they have until September 22, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Procept made false and misleading statements about its business operations and financial stability between February 28, 2024, and February 25, 2026, leading to artificial inflation of stock prices. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ:PRCT) and its officers. The lawsuit alleges that the company made materially false and misleading statements regarding its business practices, including using significant discounts to inflate revenue and misrepresenting product utilization. Investors who purchased Procept securities between February 28, 2024, and February 25, 2026, are encouraged to join the case and can apply to be lead plaintiff by September 22, 2026.
Procept BioRobotics EVP Alaleh Nouri sells $6,223 in PRCT stock
Alaleh Nouri, EVP at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 297 shares worth $6,223 to cover tax obligations from vested restricted stock units. Despite this, Nouri still holds 127,737 shares. The stock has seen a 34% year-to-date decline but the company reported a 19% increase in Q2 revenue, although procedure growth was softer than expected, leading to trimmed full-year outlooks and analyst rating adjustments.
PROCEPT BioRobotics CFO Kevin Waters Sells 373 Shares in Tax Withholding Transaction
Kevin Waters, CFO of PROCEPT BioRobotics Corp, sold 373 shares of common stock on September 9, 2026, at $20.953 per share. This sale was a "sell-to-cover" transaction to meet tax withholding obligations related to RSU vesting. Following the transaction, Waters directly holds 180,355 shares of the company.
PRCT INVESTOR ALERT: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Fraud Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT withheld crucial information regarding its handpiece sales practices, particularly the use of bulk discount programs that artificially inflated reported unit sales and revenues. Investors learned the truth through a series of disclosures, leading to a significant drop in share price.
Oppenheimer reiterates Procept BioRobotics stock rating By Investing.com
Oppenheimer has reiterated a "Perform" rating on Procept BioRobotics Corp (NASDAQ:PRCT) amid ongoing discussions about its Aquablation procedure. The company faces a stock decline of 32% year-to-date, with analysts revising earnings downwards despite strong revenue growth. While the WATER-IV trial shows promise, the stock has recently experienced mixed performance with a revenue beat but softer-than-expected procedure growth, leading to lowered price targets from other firms.
PROCEPT BIOROBOTICS CORPORATION (PRCT) SHAREHOLDER ALERT
Bernstein Liebhard LLP has issued a shareholder alert for PROCEPT BioRobotics Corporation (NASDAQ: PRCT) investors, reminding them of the September 22, 2026, deadline for a securities fraud class action lawsuit. The lawsuit alleges that the company made false and misleading statements about its business operations and financial stability between February 28, 2024, and February 25, 2026, leading to investor losses. Shareholders who purchased stock during this period are encouraged to contact the firm to discuss their options.
Shareholders of PROCEPT BioRobotics Corporation (PRCT): Protect Your Rights Before September 22, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities class action lawsuit on behalf of investors in PROCEPT BioRobotics Corporation (NASDAQ:PRCT). The lawsuit alleges that the company made false statements and concealed an extensive discount program that artificially inflated sales and revenues between February 28, 2024, and February 25, 2026. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to seek recovery.
PRCT Investment Alert - PROCEPT BioRobotics Corporation Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action
This article is an investment alert from Robbins LLP, notifying stockholders of PROCEPT BioRobotics Corporation (PRCT) who have experienced significant losses to contact the firm. The alert suggests that Robbins LLP is providing information regarding a securities class action related to PRCT. The full content of the article is unavailable, as the provided text appears to be a website's navigation and footer information rather than the article itself.
PRCT INVESTOR DEADLINE: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead the PROCEPT Class Action Lawsuit Before September 22, 2026 Deadline
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) for alleged violations of the Securities Exchange Act of 1934. The lawsuit, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, claims that Procept made materially false and/or misleading statements regarding its business, operations, and financial condition between February 28, 2024, and February 25, 2026. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff before the September 22, 2026, deadline.
PRCT FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
The Rosen Law Firm is reminding purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024, and February 25, 2026, of the September 22, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements regarding its discount program, which artificially inflated sales and revenues by encouraging bulk orders beyond demand, leading to overstocking and significant financial harm. Investors who purchased during the Class Period may be entitled to compensation and are encouraged to contact the law firm to join the class action.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (Procept) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess field inventory of handpieces, which led to a significant decline in sales and an over 18% drop in stock price. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF for more information.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding inventory issues, specifically that handpiece sales materially exceeded procedures, leading to a significant inventory glut and an 18% stock decline. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF for more information.
PRCT FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRCT
The Rosen Law Firm is reminding investors who purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024, and February 25, 2026, about the September 22, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that PROCEPT made materially false and misleading statements by failing to disclose a discount program that artificially inflated sales and revenues, leading to an oversupply of products and eventual financial harm. Investors are encouraged to contact the firm to join the class action.
PROCEPT BioRobotics (PRCT) Faces Lawsuit Scrutiny After Revenue Claims So Is It A Buying Opportunity
PROCEPT BioRobotics (PRCT) is facing class-action lawsuits alleging misleading investors on sales and inflated revenue, contributing to a significant stock decline over the past year despite a recent rebound. While one narrative suggests the stock is undervalued at $25.26, a Simply Wall St discounted cash flow model indicates it may be overvalued at its current price of $21.68, raising questions about whether now is a good entry point. Investors are advised to review underlying data to form their own conclusions given the split sentiment and legal uncertainties.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with substantial losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess handpiece inventory, which led to a significant decline in sales and an over 18% drop in stock price after the company announced its Q4 2025 earnings. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF for more information on their legal rights.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess inventory of handpieces, which led to a significant decline in sales and an 18% stock drop. Investors who purchased shares between February 28, 2024, and February 25, 2026, are affected.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP
Hagens Berman Sobol Shapiro LLP has filed a securities class action against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) due to alleged undisclosed inventory issues and subsequent stock decline. The lawsuit claims PROCEPT withheld crucial information about handpiece sales practices, including an extensive discount program that artificially inflated reported unit sales. Investors are encouraged to contact the firm if they suffered substantial losses between February 28, 2024, and February 25, 2026.
PRCT DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM,
The Rosen Law Firm is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with losses exceeding $100K to secure legal counsel by the September 22, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that PROCEPT made false and misleading statements about an undisclosed discount program that artificially inflated sales and revenue. Investors who purchased common stock between February 28, 2024, and February 25, 2026, may be entitled to compensation.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) reminds investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) with significant losses that they have until September 22, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Procept and its executives failed to disclose material information regarding handpiece sales materially exceeding procedures, leading to a significant inventory glut and an 18% stock decline following the announcement of Q4 and year-end 2025 earnings. Investors who purchased shares between February 28, 2024, and February 25, 2026, are encouraged to contact KSF to discuss their legal rights.
PROCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that Procept misled investors by failing to disclose an extensive discount program that artificially inflated sales and revenues, leading to overstocked inventory and ultimately causing investor damages. Investors have until September 22, 2026, to apply for lead plaintiff status.
PROCEPT BioRobotics Corporation $PRCT Shares Purchased by Bank of America Corp DE
Bank of America Corp DE increased its stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 46.3% in the first quarter, owning 630,689 shares valued at $15.77 million. Other institutional investors also adjusted their holdings, while analyst ratings for PRCT are mixed, resulting in a consensus "Hold" rating and a target price of $28.00. The company faces ongoing securities fraud lawsuits, impacting investor sentiment, despite reporting revenues of $94.50 million for the quarter.
PRCT INVESTOR DEADLINE: RGRD Law Files Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who purchased stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT made materially false and misleading statements by failing to disclose an extensive discount program that artificially inflated sales and revenues, leading to a significant overstock of handpiece units. Investors with substantial losses have until September 22, 2026, to seek appointment as lead plaintiff in the case.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that they have until September 22, 2026, to file as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Procept failed to disclose material information regarding excess inventory of handpieces, which led to a significant decline in sales and an over 18% drop in stock price. Investors who purchased shares between February 28, 2024, and February 25, 2026, and incurred substantial losses are encouraged to contact KSF.
Kaplan Fox Announces a Securities Class Action Filed Against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) - Lead Plaintiff Deadline is September 22, 2026
Kaplan Fox & Kilsheimer LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors who purchased common stock between February 28, 2024, and February 25, 2026. The lawsuit alleges that PROCEPT artificially inflated its reported U.S. handpiece unit sales and revenues by concealing that its discount program caused handpiece orders to materially exceed procedures. Investors who suffered losses are encouraged to contact Kaplan Fox, with a lead plaintiff deadline of September 22, 2026.
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors May Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) due to alleged undisclosed inventory issues and a significant stock decline. The lawsuit claims PROCEPT withheld crucial information about handpiece sales practices, using an extensive discount program that artificially inflated sales by encouraging bulk orders beyond customer demand. Investors reportedly learned the truth through a series of disclosures that led to a substantial drop in share price.
